Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin Open-Label Extension in Schizophrenia
NCT03121586Phase 3Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of pimavanserin in schizophrenia, sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment Emergent Adverse Events at 30 days. Started Jan 2017; status: terminated.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03121586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121586.